Trial reportBMC psychiatry2017
Factors related to the improvement in quality of life for depressed inpatients treated with fluoxetine.
Trial report in BMC psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01075529 (Model for Early Prediction of Clinical Response in Patients With Major Depression Receiving Fluoxetine), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Model for Early Prediction of Clinical Response in Patients With Major Depression Receiving Fluoxetine
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Predictors of Changes in Quality of Life of Patients with Major Depressive Disorder-A Prospective Naturalistic 3-Month Follow-Up Study.Journal of clinical medicine · 2023Article
- Association between social support and depressive symptoms among Chinese nurses with formal employment versus contract-based employment.Frontiers in psychiatry · 2023Article
- Relationship between social support, anxiety, and depression among frontline healthcare workers in China during COVID-19 pandemic.Frontiers in psychiatry · 2022Article
- Changes in treatment outcomes in patients undergoing an integrated psychosomatic inpatient treatment: Results from a cohort study.Frontiers in psychiatry · 2022Article
- Article
- Independent and Joint Impacts of Acid-Producing Diets and Depression on Physical Health among Breast Cancer Survivors.Nutrients · 2021Article
- Fear of future workplace violence and its influencing factors among nurses in Shandong, China: a cross-sectional study.BMC nursing · 2021Article
- Social support and depressive symptoms among physicians in tertiary hospitals in China: a cross-sectional study.BMC psychiatry · 2021Article
- Machine Learning Prediction of Treatment Outcome in Late-Life Depression.Frontiers in psychiatry · 2021Article
- Global mapping of interventions to improve quality of life of patients with depression during 1990-2018.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020Review
- Quality of Life Assessment in Antidepressant Treatment of Patients with Depression and/or Anxiety Disorder.Materia socio-medica · 2019Article
- Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study.Neuropsychiatric disease and treatment · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to explore the relationships between depressive symptoms and health-related quality of life (HRQOL) measurements for inpatients with major depressive disorder (MDD) before and after 6-week fluoxetine treatment, and to elucidate the factors related to the HRQOL changes.
methodsA total of 131 inpatients with MDD were enrolled to receive 20 mg of fluoxetine for 6 weeks. Symptom severity and adverse events were assessed at weeks 0, 1, 2, 3, 4, and 6 using the 17-item Hamilton Depression Rating Scale (HAMD-17) and UKU Side Effect Rating Scale, respectively. HRQOL was measured using the Short Form 36 (SF-36), including 8 subscales, physical component summary (PCS) and mental component summary (MCS), at baseline and week 6. Spearman's coefficient, Cohen's d, and multiple linear regression model were used for statistical analysis.
resultsOne hundred and six patients completing all measures at weeks 0 and 6 entered the analysis. HAMD-17 negatively correlated with SF-36 at baseline and week 6. The HAMD-17 had a larger effect size than SF-36. MCS, rather than PCS, showed statistically significant improvement. After using multiple linear regression analysis, age at onset, HAMD-17 score change, and number of adverse events reported during the trial period were related to MCS change after adjusting for confounding variables.
conclusionsFluoxetine treatment was associated with an improvement in depressive symptomology and HRQOL. Depressive symptoms had a greater extent of change than HRQOL. Clinicians must consider the negative effects of adverse events caused by antidepressants on the improvement of HRQOL.
trial registrationhttp://clinicaltrials.gov , NCT01075529 , retrospectively registered 24/2/2010.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.